Lord, Abbett & Co
IOVA icon

Lord, Abbett & Co’s Iovance Biotherapeutics IOVA Stock Holding History

Lord, Abbett & Co’s Portfolio IOVA Stock Details IOVA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q2 		– Sell
-1,097,031
Closed -$34.7M – 668
2021
Q1 		$34.7M Sell
1,097,031
-2,087,457
-66% -$86.5M 0.09% 328
2020
Q4 		$148M Buy
3,184,488
+1,338,048
+72% +$53.1M 0.39% 63
2020
Q3 		$60.8M Buy
1,846,440
+69,311
+4% +$2.12M 0.19% 163
2020
Q2 		$48.8M Buy
1,777,129
+1,180,398
+198% +$38.8M 0.17% 189
2020
Q1 		$17.9M Buy
+596,731
New +$15.8M 0.08% 337

Other funds holding IOVA

AIM
ARK Investment Management St. Petersburg, Florida $15.4B AUM 50.29% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
PA
Perceptive Advisors New York $6.66B AUM 360.84% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $11.1B AUM 207.82% 1-Year Est. Return
Sumitomo Mitsui Trust Group
Sumitomo Mitsui Trust Group Minato-Ku, Tokyo, Japan $175B AUM 40.63% 1-Year Est. Return
NAMA
Nikko Asset Management Americas New York $7.75B AUM 33.73% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $462B AUM 39.16% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
O
OrbiMed New York $5.4B AUM 163.13% 1-Year Est. Return

Lord, Abbett & Co's IOVA Position: Q2 2021 in Review

Lord, Abbett & Co sold out of Iovance Biotherapeutics (IOVA) in Q2 2021, closing a stake of 1,097,031 shares — an estimated $34.7M sold.

Lord, Abbett & Co first reported a position in IOVA in Q1 2020 and held it in 5 quarters. The position peaked at $148M in Q4 2020. 234 funds tracked by Wall St. Rank hold IOVA as of Q2 2021.

  • Lord, Abbett & Co reported no remaining Iovance Biotherapeutics position as of Q2 2021 after selling out during the quarter.
  • Lord, Abbett & Co sold 1,097,031 Iovance Biotherapeutics shares in Q2 2021, an estimated $34.7M.
  • Lord, Abbett & Co first reported a position in Iovance Biotherapeutics in Q1 2020 and held it in 5 quarters.
  • Lord, Abbett & Co's Iovance Biotherapeutics position peaked at $148M in Q4 2020.
  • 234 funds tracked by Wall St. Rank held Iovance Biotherapeutics as of Q2 2021.

Based on Lord, Abbett & Co's 13F filing for Q2 2021, filed 11 Aug 2021.